SecBot SecBot

SCYX drug pipeline

SCYNEXIS INC · 3 rated drugs
$2.91
−9.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1 completed; Phase 2 ready
Time to marketMinimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)

SCY-770 Updated Oct 25

What to watch

Watch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.

Bull case
  • First-in-class mechanism targeting root cause of ADPKD with no disease-modifying oral options beyond Tolvaptan (Jynarque), which has tolerability issues
  • FDA Orphan Drug Designation provides 7-year market exclusivity, regulatory fee waivers, and potential accelerated approval via total kidney volume surrogate endpoint
  • Phase 1 showed clean safety at doses higher than previously tested, 273 subjects dosed across 8 trials with prior PXL770 studies, supporting the dose range for Phase 2
Bear case
  • SCY-770 has ZERO efficacy data in ADPKD patients, the prior PXL770 Phase 2a in NASH (a different disease) missed its primary endpoint on liver fat reduction
  • Phase 2 is still a proof-of-concept study; the early efficacy readout (H2 2027) is binary and could fail to show meaningful total kidney volume reduction
  • Tolvaptan (Jynarque, Otsuka) is already approved and established with a large treated population; competitive entrant needs to demonstrate superiority or better tolerability
◆ mixed
Impact
PhasePhase 1 completed; Phase 2 expected 2027
Time to marketEstimated 4-6+ years, assuming successful Phase 2, Phase 3, and NDA review—no earlier than ~2030

SCY-247 Updated Oct 25

What to watch

The next catalyst for SCY-247 is the initiation of a Phase 2 trial in invasive candidiasis, expected in 2027 (subject to FDA agreement). A pipeline presentation at IDWeek (Oct 21-25, 2026) may provide updates on development timelines. Phase 2 topline efficacy data, the first human proof-of-concept in patients, would be the next major binary event, likely 12+ months after enrollment begins.

Bull case
  • FDA QIDP designation provides at least 10 years of market exclusivity upon approval, plus Fast Track enabling accelerated pathways and rolling review (source: ir.scynexis.com/news/detail/356)
  • BARDA contract worth up to ~$214M in non-dilutive funding, with $18.5M initial base period, validates the program's government interest in addressing antifungal resistance and reduces dilution risk (source: ir.scynexis.com/news/detail/372)
  • Phase 1 IV study completed Oct 2026 showed favorable safety, tolerability, and PK at target exposures at ≥50 mg doses, supporting dose selection for Phase 2 (source: ir.scynexis.com/news/detail/375)
Bear case
  • SCY-247 is early-stage, only Phase 1 data in healthy volunteers exist. Human proof-of-concept in infected patients (Phase 2) has not been initiated and will not read out until 2028+ even if enrollment starts in 2027 (source: ir.scynexis.com/news/detail/375)
  • Competition is entrenched: echinocandins (micafungin, caspofungin, Merck's rezafungin) are the standard-of-care for invasive candidiasis, and azoles dominate the oral market. GSK (partner for first-gen ibrexafungerp) holds right of first negotiation on next-gen compounds, potentially limiting deal flexibility (source: fiercebiotech.com)
  • The BARDA contract's full $214M is contingent on milestone achievements and option exercises, only $18.5M is committed upfront. If milestones are missed, the funding falls far short (source: ir.scynexis.com/news/detail/372)
● neutral
Impact
PhaseApproved
Time to marketAlready approved but commercially unavailable; GSK is working on a relaunch with no confirmed date as of October 2026. Shortage tracking shows 0% pharmacy availability.

BREXAFEMME ibrexafungerp Updated Oct 25

What to watch

There is no hard, dated binary catalyst for BREXAFEMME itself, it is already approved and the commercial relaunch by GSK has no confirmed timeline. SCYX investors should watch the Q3 2026 earnings call (estimated Nov 11) for any GSK relaunch updates, and the start of SCY-770 Phase 2 PoC in ADPKD (expected Q4 2026) as the company's next value-driving pipeline catalyst.

Bull case
  • BREXAFEMME is the first new antifungal class in >20 years and the only FDA-approved oral non-azole for both VVC and recurrent VVC, giving it a strong differentiation story if GSK relaunches.
  • The GSK license provides SCYX with up to $145.5M in annual net sales milestones plus low-to-mid single-digit royalties, representing substantial non-dilutive upside if the drug returns to market.
  • Analyst consensus is Strong Buy (8 analysts: 5 buy, 3 strong buy, 1 hold) with a mean price target of ~$36.33, implying ~860% upside from the ~$3.79 stock price.
Bear case
  • BREXAFEMME has been off the market since September 2023 due to a contamination-related recall, and as of late October 2026 it still has 0% pharmacy availability with no confirmed GSK relaunch date, over 3 years of commercial absence.
  • The 19-month FDA clinical hold and manufacturing issues raise questions about production reliability and GSK's ability to resolve FDA concerns quickly.
  • SCYX completed a 1-for-8 reverse stock split in June 2026 to maintain Nasdaq listing, signaling distress, and issued a $37.2M private placement that diluted existing holders.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
BREXAFEMMEA Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazolePhase 3Terminated · results68Nov 7, 2025